Bicara Therapeutics Inc [BCAX] stock is trading at $18.51, up 4.11%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCAX shares have gain 2.66% over the last week, with a monthly amount glided 59.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $36. Previously, Wells Fargo upgraded its rating to Equal Weight on May 23, 2025, and kept the price target unchanged to $8. On April 17, 2025, Wells Fargo initiated with a Underweight rating and assigned a price target of $8 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $31 on February 06, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $42 as its price target on December 06, 2024. Rodman & Renshaw started tracking with a Buy rating for this stock on November 05, 2024, and assigned it a price target of $48. In a note dated October 08, 2024, TD Cowen initiated an Buy rating.
Bicara Therapeutics Inc [BCAX] stock has fluctuated between $7.80 and $28.09 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $18.51 at the most recent close of the market. An investor can expect a potential return of 29.66% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.22 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Bicara Therapeutics Inc’s Current Ratio is 25.80. In addition, the Quick Ratio stands at 25.80 and the Cash Ratio stands at 25.34.
Transactions by insiders
Recent insider trading involved Raben David, Chief Medical Officer, that happened on Oct 09 ’25 when 22000.0 shares were sold. Chief Financial Officer, Hyep Ivan completed a deal on Oct 09 ’25 to sell 6415.0 shares. Meanwhile, Officer Hyep Ivan bought 6415.0 shares on Oct 09 ’25.
